Are target-family-privileged substructures truly privileged?

被引:82
作者
Schnur, DM [1 ]
Hermsmeier, MA [1 ]
Tebben, AJ [1 ]
机构
[1] Bristol Myers Squibb Co, Pharmaceut Res Inst, Princeton, NJ 08543 USA
关键词
D O I
10.1021/jm0502900
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
One of the early and effective approaches to G-coupled protein receptor target family library design was the analysis of a set of ligands for frequently occurring chemical moieties or substructures. Various methods ranging from frameworks analysis to pharmacophores have been employed to find these so-called target-family-privileged substructures. Although the use of these substructures is common practice in combinatorial library design and has produced leads,(1) the methods used for finding them rarely verified their selectivity for the particular target family from which they were derived. The frequency of occurrence among ligands associated with a target receptor family is not a sufficient criterion for those substructures to receive the label of target-family-privileged substructure. This study explores the question of selectivity of ClassPharmer(2) generated fragments for a series of target families: GPCRs, nuclear hormone receptors, serine proteases, protein kinases, and ligand-gated ion channels. In addition, a GPCR focused library and a random set of 10k compounds are examined in terms of their target-family-privileged-substructure composition. The results challenge the combinatorial chemistry concept of target-family-privileged substructures and suggest that many of these fragments may simply be drug-like or attractive for various receptors in accordance with the original definition of privileged substructures.(3,4)
引用
收藏
页码:2000 / 2009
页数:10
相关论文
共 26 条
[1]   Predictive in silico modeling for hERG channelblockers [J].
Aronov, MM .
DRUG DISCOVERY TODAY, 2005, 10 (02) :149-155
[2]   The selection and design of GPCR ligands: From concept to the clinic [J].
Ashton, M ;
Charlton, MH ;
Schwarz, MK ;
Thomas, RJ ;
Whittaker, M .
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2004, 7 (05) :441-452
[3]   The properties of known drugs .1. Molecular frameworks [J].
Bemis, GW ;
Murcko, MA .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (15) :2887-2893
[4]   Ligand identification for G-protein-coupled receptors: a lead generation perspective [J].
Bleicher, KH ;
Green, LG ;
Martin, RE ;
Rogers-Evans, M .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2004, 8 (03) :287-296
[5]   Recognition of privileged structures by G-protein coupled receptors [J].
Bondensgaard, K ;
Ankersen, M ;
Thogersen, H ;
Hansen, BS ;
Wulff, BS ;
Bywater, RP .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (04) :888-899
[6]  
Demuth H U, 1990, J Enzyme Inhib, V3, P249, DOI 10.3109/14756369009030375
[7]   METHODS FOR DRUG DISCOVERY - DEVELOPMENT OF POTENT, SELECTIVE, ORALLY EFFECTIVE CHOLECYSTOKININ ANTAGONISTS [J].
EVANS, BE ;
RITTLE, KE ;
BOCK, MG ;
DIPARDO, RM ;
FREIDINGER, RM ;
WHITTER, WL ;
LUNDELL, GF ;
VEBER, DF ;
ANDERSON, PS ;
CHANG, RSL ;
LOTTI, VJ ;
CERINO, DJ ;
CHEN, TB ;
KLING, PJ ;
KUNKEL, KA ;
SPRINGER, JP ;
HIRSHFIELD, J .
JOURNAL OF MEDICINAL CHEMISTRY, 1988, 31 (12) :2235-2246
[8]   Computational Modeling approaches to structure-function analysis of G protein-coupled receptors [J].
Fanelli, F ;
De Benedetti, PG .
CHEMICAL REVIEWS, 2005, 105 (09) :3297-3351
[9]   Privileged molecules for protein binding identified from NMR-based screening [J].
Hajduk, PJ ;
Bures, M ;
Praestgaard, J ;
Fesik, SW .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (18) :3443-3447
[10]   The combinatorial synthesis of bicyclic privileged structures or privileged substructures [J].
Horton, DA ;
Bourne, GT ;
Smythe, ML .
CHEMICAL REVIEWS, 2003, 103 (03) :893-930